Daniel Pascale, Raad Marc, Waked Rami, Choucair Jacques, Riachy Moussa, Haddad Fady
Department of Internal Medicine and Clinical Immunology, Hotel-Dieu de France University Hospital, Saint Joseph University, Beirut, Lebanon.
Department of Pulmonary and Critical Care Medicine, Hotel-Dieu de France University Hospital, Saint Joseph University, Beirut, Lebanon.
Eur J Case Rep Intern Med. 2020 Sep 24;7(10):001922. doi: 10.12890/2020_001922. eCollection 2020.
The coronavirus disease COVID-19 is considered a pandemic disease that has developed rapidly all over the world. As of today, it is unclear whether immunosuppression confers an increased risk for pulmonary complications, or conversely, whether it can be a protective factor with respect to a cytokine storm.
We report the case of a 55-year-old male patient with granulomatosis with polyangiitis treated with rituximab who was infected with COVID-19 pneumonia. To the best of our knowledge, only 1 case has been reported in the literature with similar characteristics. The patient had a non-classic evolution of clinical symptoms with persistent fever and viral shedding, in addition to a negative serology.
This case emphasizes the management and immunity response to COVID-19 pneumonia in such patients. Data are still needed regarding patients who have prolonged B-cell depletion, which may put the patient at a higher risk for reinfection.
Demonstration of the immunity response to COVID-19 pneumonia in an immunosuppressed patient.To highlight the management and evolution of such rare cases during this pandemic.
冠状病毒病COVID-19被认为是一种在全球迅速蔓延的大流行病。截至目前，尚不清楚免疫抑制是否会增加肺部并发症的风险，或者相反，它是否可能是针对细胞因子风暴的保护因素。
我们报告了一例55岁接受利妥昔单抗治疗的肉芽肿性多血管炎男性患者感染COVID-19肺炎的病例。据我们所知，文献中仅报道过1例具有类似特征的病例。该患者临床症状呈非典型演变，持续发热且病毒持续排出，此外血清学检测呈阴性。
该病例强调了此类患者对COVID-19肺炎的管理和免疫反应。对于B细胞长期耗竭的患者，仍需要更多数据，这可能使患者面临更高的再次感染风险。
展示免疫抑制患者对COVID-19肺炎的免疫反应。强调在此次大流行期间对此类罕见病例的管理和病情演变。
